Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Challenges and Insights from the Mepolizumab Pregnancy Exposure Study.Drug safety · 2026
   Review
2. Post-marketing safety evaluation and objective benefit-risk assessment of sublingual immunotherapy tablets in allergic rhinitis.Naunyn-Schmiedeberg's archives of pharmacology · 2026
   Article
3. Evaluating the effectiveness of AI-enhanced "One Body, Two Wings" pharmacovigilance models in China: a nationwide survey on medication safety and risk management.Frontiers in health services · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.